In vitro susceptibility profile of Brazilian Sporothrix brasiliensis isolates to amorolfine hydrochloride and itraconazole.

IF 2.3 3区医学 Q3 INFECTIOUS DISEASES

Medical mycology Pub Date : 2025-09-02 DOI:10.1093/mmy/myaf075

Luciéle Pereira de Melo, Caroline Quintana Braga, Carolina Dos Santos Bermann, Lara Baccarin Ianiski, Jefferson Luiz Silva de Souza, Jéssica Rabelo de Oliveira Persichini, Angelita Dos Reis Gomes, Renata Osório de Faria, Maria Isabel de Azevedo, Sônia de Avila Botton, Daniela Isabel Brayer Pereira

引用次数: 0

Abstract

Sporothrix brasiliensis is the leading cause of feline sporotrichosis in Brazil, an emerging zoonosis. Itraconazole (ITZ) is the first-line therapy; however, therapeutic failures and reports of ITZ-resistant isolates emphasize the need for new therapeutic options. This study evaluated the in vitro susceptibility profile of 25 Brazilian S. brasiliensis isolates to amorolfine hydrochloride (AMR) and ITZ. AMR evidenced fungicidal activity in 76% and fungistatic activity in 24% of isolates. All isolates were susceptible to ITZ. These findings support AMR as a promising antifungal candidate against S. brasiliensis and highlight the importance of continued surveillance of ITZ susceptibility, especially in endemic regions of Brazil.

查看原文本刊更多论文

巴西孢子丝虫对盐酸阿莫罗芬和伊曲康唑的体外敏感性分析。

巴西孢子丝虫是巴西猫孢子虫病的主要原因，这是一种新兴的人畜共患病。伊曲康唑（Itraconazole， ITZ）为一线治疗药物；然而，治疗失败和itz耐药分离株的报告强调需要新的治疗选择。研究了25株巴西巴西葡萄球菌对盐酸阿莫罗fine （AMR）和ITZ的体外敏感性。AMR显示76%的菌株有杀真菌活性，24%的菌株有抑真菌活性。所有分离株均对ITZ敏感。这些发现支持AMR作为一种有希望的抗巴西葡萄球菌候选抗真菌药物，并强调了持续监测其易感性的重要性，特别是在巴西流行地区。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.